. Author manuscript; available in PMC: 2016 Jul 29.

Published in final edited form as: J Pediatr Gastroenterol Nutr. 2013 Oct;57(4):438–443. doi: 10.1097/MPG.0b013e31829ef4b4

Table 1.

Source of liver specimens/DNA samples

	n
Previously healthy liver transplant (LT) donors (healthy controls)	65
Individuals with known mtDNA depletion (mtDNA depletion controls)	18
Patients with liver disease of known etiology requiring LT (LT controls)	28
Extra hepatic biliary atresia	12
PFIC1	6
Wilson Disease	5
Tyrosinemia Type 1	3
Alagille Syndrome	2
Healthy individuals^* (population controls)	205
Patients with fulminant hepatic failure (FHF) undergoing LT (FHF test group)	45
Viral-induced FHF	10
Drug-induced FHF	17^”
FHF due to unknown cause	18

DNA was obtained from liver samples except in this group of individuals in whom DNA was obtained from blood samples.

^”

one sample was too degraded to extract DNA, and in a further sample the DNA was insufficient quality to perform sequencing.